183 related articles for article (PubMed ID: 34911681)
1. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Luginbuhl AJ; Johnson JM; Harshyne LA; Linnenbach AJ; Shukla SK; Alnemri A; Kumar G; Cognetti DM; Curry JM; Kotlov N; Antysheva Z; Degryse S; Mannion K; Gibson MK; Netterville J; Brown B; Axelrod R; Zinner R; Tuluc M; Gargano S; Leiby BE; Shimada A; Mahoney MG; Martinez-Outschoorn U; Rodeck U; Kim YJ; South AP; Argiris A
Clin Cancer Res; 2022 Mar; 28(5):915-927. PubMed ID: 34911681
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
3. Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
Alnemri AE; Tekumalla S; Moroco AE; Vathiotis I; Tuluc M; Gargano S; Zhan T; Cognetti DM; Curry JM; Argiris A; Linnenbach A; South AP; Harshyne LA; Johnson JM; Luginbuhl AJ
Cancer Med; 2024 Jun; 13(11):e7370. PubMed ID: 38847087
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL; Elbers JBW; Krijgsman O; Traets JJH; Qiao X; van der Leun AM; Lubeck Y; Seignette IM; Smit LA; Willems SM; van den Brekel MWM; Dirven R; Baris Karakullukcu M; Karssemakers L; Klop WMC; Lohuis PJFM; Schreuder WH; Smeele LE; van der Velden LA; Bing Tan I; Onderwater S; Jasperse B; Vogel WV; Al-Mamgani A; Keijser A; van der Noort V; Broeks A; Hooijberg E; Peeper DS; Schumacher TN; Blank CU; de Boer JP; Haanen JBAG; Zuur CL
Nat Commun; 2021 Dec; 12(1):7348. PubMed ID: 34937871
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
[TBL] [Abstract][Full Text] [Related]
7. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
Wang X; Muzaffar J; Kirtane K; Song F; Johnson M; Schell MJ; Li J; Yoder SJ; Conejo-Garcia JR; Guevara-Patino JA; Bonomi M; Bhateja P; Rocco JW; Steuer CE; Saba NF; Chung CH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35676062
[TBL] [Abstract][Full Text] [Related]
8. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
9. IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.
Hill BL; Calder AN; Flemming JP; Guo Y; Gilmore SL; Trofa MA; Daniels SK; Nielsen TN; Gleason LK; Antysheva Z; Demina K; Kotlov N; Davitt CJH; Cognetti DM; Prendergast GC; Snook AE; Johnson JM; Kumar G; Linnenbach AJ; Martinez-Outschoorn U; South AP; Curry JM; Harshyne LA; Luginbuhl AJ; Mahoney MG
Mol Carcinog; 2023 Sep; 62(9):1428-1443. PubMed ID: 37401875
[TBL] [Abstract][Full Text] [Related]
10. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect.
Merlino DJ; Johnson JM; Tuluc M; Gargano S; Stapp R; Harshyne L; Leiby BE; Flanders A; Zinner R; Axelrod R; Curry J; Cognetti DM; Mannion K; Kim YJ; Rodeck U; Argiris A; Luginbuhl AJ
Front Oncol; 2020; 10():566315. PubMed ID: 33344227
[TBL] [Abstract][Full Text] [Related]
11. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer.
Redman JM; Friedman J; Robbins Y; Sievers C; Yang X; Lassoued W; Sinkoe A; Papanicolau-Sengos A; Lee CC; Marte JL; Turkbey E; Mydlarz W; Joshi A; London NR; Pierce M; Taylor R; Hong S; Nguyen A; Soon-Shiong P; Schlom J; Gulley JL; Allen CT
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35727629
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
Califano JA; Khan Z; Noonan KA; Rudraraju L; Zhang Z; Wang H; Goodman S; Gourin CG; Ha PK; Fakhry C; Saunders J; Levine M; Tang M; Neuner G; Richmon JD; Blanco R; Agrawal N; Koch WM; Marur S; Weed DT; Serafini P; Borrello I
Clin Cancer Res; 2015 Jan; 21(1):30-8. PubMed ID: 25564570
[TBL] [Abstract][Full Text] [Related]
13. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
Ferrarotto R; Amit M; Nagarajan P; Rubin ML; Yuan Y; Bell D; El-Naggar AK; Johnson JM; Morrison WH; Rosenthal DI; Glisson BS; Johnson FM; Lu C; Mott FE; Esmaeli B; Diaz EM; Gidley PW; Goepfert RP; Lewis CM; Weber RS; Wargo JA; Basu S; Duan F; Yadav SS; Sharma P; Allison JP; Myers JN; Gross ND
Clin Cancer Res; 2021 Aug; 27(16):4557-4565. PubMed ID: 34187851
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Weed DT; Vella JL; Reis IM; De la Fuente AC; Gomez C; Sargi Z; Nazarian R; Califano J; Borrello I; Serafini P
Clin Cancer Res; 2015 Jan; 21(1):39-48. PubMed ID: 25320361
[TBL] [Abstract][Full Text] [Related]
16. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Uppaluri R; Campbell KM; Egloff AM; Zolkind P; Skidmore ZL; Nussenbaum B; Paniello RC; Rich JT; Jackson R; Pipkorn P; Michel LS; Ley J; Oppelt P; Dunn GP; Barnell EK; Spies NC; Lin T; Li T; Mulder DT; Hanna Y; Cirlan I; Pugh TJ; Mudianto T; Riley R; Zhou L; Jo VY; Stachler MD; Hanna GJ; Kass J; Haddad R; Schoenfeld JD; Gjini E; Lako A; Thorstad W; Gay HA; Daly M; Rodig SJ; Hagemann IS; Kallogjeri D; Piccirillo JF; Chernock RD; Griffith M; Griffith OL; Adkins DR
Clin Cancer Res; 2020 Oct; 26(19):5140-5152. PubMed ID: 32665297
[TBL] [Abstract][Full Text] [Related]
18. Metformin Effects on FOXP3
Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of cetuximab plus PD-1 inhibitor differs by HPV status in head and neck squamous cell carcinoma: a systematic review and meta-analysis.
Zhang S; Zheng M; Nie D; Xu L; Tian H; Wang M; Liu W; Feng Z; Han F
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253001
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial.
Zhang Z; Wu B; Peng G; Xiao G; Huang J; Ding Q; Yang C; Xiong X; Ma H; Shi L; Yang J; Hong X; Wei J; Qin Y; Wan C; Zhong Y; Zhou Y; Zhao X; Leng Y; Zhang T; Wu G; Yao M; Zhang X; Yang K
Clin Cancer Res; 2022 Aug; 28(15):3268-3276. PubMed ID: 35766967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
